Replies to post #200628 on NorthWest Biotherapeutics Inc (NWBO)

[Basin Street Blues]

A Licensing agreement checks all boxes .

1. Upfront to the company

&

2. Milestone payments on positive top line , on approval , on trial instigation of D , on top line of different indication etc etc..

Net net a $10bn ++ deal that large pharma would probably only have to put $500m ` at risk ` via the upfront NOW.

I think its that `upfront risk ` number that is being discussed with
several parties.

[BioInfo]

I strongly believe that there will be no partnerships. LP clearly stated that GBM trial they can finish long time ago and now there are no more big expenses left other than collect the data and present. Data appears good and no need for outside help when you can have it all. Once market gets wind of relationship hard data share price will skyrocket.

LP knows this and this may be No. 1 reason BP hates NWBO and has gotten folks against them to have them fail and scoop on cheap. That time has come and gone now. LP may have shown middle finger to all.of them.

[VuBru]

Flip - I keep coming back to the fact that there was no reason for them to announce delay of 3Q results due to ongoing negotiations, even for one day as turned out to be the case. The 3Q results were already locked into place at the time of announcement (any negotiations would only affect things going forward in Q4). Only reason to make that delay announcement was to get info out there that they were in late stage parallel negotiations for alternative financings. They clearly wanted someone to know. There would be no reason to make this type of announcement if it were simply another dilution or toxic financing. No idea what it is, but it is something different than in the past couple of years.